Democrats on Capitol Hill are continuing their efforts to increase prescription drug regulation by introducing measures to expand the Food and Drug Administration’s (FDA) authority “by requiring drug approvals to be paired with programs to manage risk once they reach the market.†(Source)
One issue of contention is whether to use the user-fee agreement between the FDA and drug companies to implement these changes. The user-fee agreement will expire this year.
Wall Street Journal subscribers can read details of the story here.
